Looking at options history for BioNTech BNTX we detected 11 trades. If we consider the specifics of each trade, it is ...

According to CNN, the shares of leading vaccine manufacturers plummeted on Thursday after President-elect Donald Trump ...

Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F.

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, approximately $5B and $5.5B, respectively. Including the contribution ...